Ascendis continued big investments into 2021, driving operating deficit up
![Photo: Kevin Grønnemann / MedWatch](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13791983.ece/ALTERNATES/schema-16_9/doc7jylz7dkona1ctb8d75e.jpg)
Danish biotech company Ascendis Pharma, which is listed in the US, continued on its growth track in 2021, booking a revenue of EUR 7.8m compared to preceding year’s EUR 7.8m, the company’s full-year report states.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Ascendis Pharma initiates clinical trial of dwarfism drug
For subscribers